Validation of a New Innovative Method for Specific Marker Detection in

Status Recruiting

Clinical Trial Summary

Celiac disease (CD) is a common auto-immune disorder induced by gluten ingestion in genetically susceptible individuals (HLA-DQ2/DQ8). Gluten induces small-bowel villous atrophy and a specific immune response characterized by the production of CD-autoantibodies against transglutaminase 2 (anti-TG2) and endomysium (EMA). In symptomatic patients with positive-serum antibodies and villous atrophy, the diagnosis of CD is clearcut. However, 10-30% of patients evaluated for suspected CD show only mild histopathologic changes and fluctuating serologic markers, a condition identified as potential CD. In such cases the diagnosis may remain uncertain. CD-autoantibodies are produced by intestinal B-cells in the early phases of the disease, before their appearance in the serum and when the duodenal mucosa is still normal. Intestinal CD-antibodies (I-CD-abs) are a marker of CD, have a high sensitivity and specificity for CD and identify those patients with potential CD who are at risk of progression to villous atrophy. I-CD-abs can be detected by double immunofluorescence staining on frozen duodenal sections or by using an endomysial antibody assay in the culture medium of duodenal biopsies (EMAbiopsy). The diagnostic accuracy of these techniques is comparable as they both have high sensitivity and specificity. However, their implementation in clinical practice is limited because they require both experienced operators and well-equipped laboratories. There is an unmet need: the development of a new simple and effective diagnostic tool that any gastroenterology unit can use in routine diagnostics to ensure a prompt diagnosis in suspected CD patients, who may benefit from a therapy based on gluten-free diet, and to reduce both unnecessary medical investigations and diagnostic delays. In order to simplify and shorten times for the detection of these intestinal antibodies, the study aims to substitute the EMAbiopsy assay with a supernatant obtained quickly after mechanical lysis of fresh intestinal biopsy specimen. The obtained samples will be tested with rapid (about 15 minutes) immune-chromatographic anti-TG2 assay (Rapid Intestinal anti-TG2 Assay).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06324539
Study type	Observational
Source	IRCCS Burlo Garofolo
Contact	Alberto Tommasini, MD PhD Prof
Phone	+39.040.3785.422
Email	alberto.tommasini@burlo.trieste.it
Status	Recruiting
Phase
Start date	October 4, 2023
Completion date	May 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04440501` - Virtual Reality to Teach, Improve Outcomes, and Engage (VIRTUE): Virtual Reality to Improve Gluten-Free Diet Knowledge in Pediatric Celiac Disease	N/A
Enrolling by invitation	`NCT06179121` - "Adding DNA-test for Screening of HLA-DQ2 and DQ8 to Improve Early Diagnosis of Celiac Disease"
Completed	`NCT06359613` - Efficacy Assessment of Gluten Free Cupcakes	N/A
Active, not recruiting	`NCT05548166` - Development of CELIAC-Q KIDS: A Patient-Reported Outcome Measure for Pediatric Celiac Disease
Recruiting	`NCT04014660` - Prevention av Autoimmunitet Med Laktobaciller	N/A
Not yet recruiting	`NCT04019223` - Anti-Tissue Transglutaminase IgA Antibodies
Completed	`NCT03966625` - Serological Identification of Celiac Disease in Kids
Not yet recruiting	`NCT03244254` - Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients	N/A
Recruiting	`NCT05132725` - Carbohydrate Counting and DASH Intervention Among Children With Diabetes and Celiac Disease.	N/A
Enrolling by invitation	`NCT05084937` - Celiac Disease in Childhood-Adulthood Transition	N/A
Recruiting	`NCT04593888` - Gluten Reduction and Risk of Celiac Disease	N/A
Not yet recruiting	`NCT06364735` - Entities and Variables Related to Catch-up Growth
Completed	`NCT04272983` - Population Study of the Prevalence of Celiac Disease and Other Gluten-dependent Disorders in Children and Adolescents
Not yet recruiting	`NCT06149507` - Effect of Acetaminophen Versus Ibuprofen in Treating Recurrent Apthous Ulcers in Pediatric Celiac Disease	Phase 4
Completed	`NCT04240340` - Experiences of Disclosure in Adolescents With Coeliac Disease
Completed	`NCT03176095` - Celiac Disease Prevention With Probiotics	N/A
Active, not recruiting	`NCT06038344` - Influence of a Gluten Free Food Guide on Diet Quality and Adherence to the GFD in Youth With Celiac Disease	N/A
Completed	`NCT04533776` - Support for Adolescents With Celiac Disease	N/A
Completed	`NCT03663309` - Assessment of Adherence to Gluten Free Diet in Children and Adolescents by Detection of Gluten in Faecal Samples.
Not yet recruiting	`NCT06206616` - Liver Steatosis in Pediatric CD Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Validation of a New Innovative Method for Specific Marker Detection in Celiac Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms